Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC

Bibliography

• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343(21):1520-8. 2 p following 8
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352(11):1092-102
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352(11):1071-80
   PubMed Web of Science ®Google Scholar
• Ray WA, Stein CM, Hall K, et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002;359(9301):118-23
   PubMed Web of Science ®Google Scholar
• Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365(9458):475-81
   PubMed Web of Science ®Google Scholar
• Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360(9339):1071-3
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011;8(9):e1001098
   PubMed Web of Science ®Google Scholar
• Singh G, Wu O, Langhorne P, et al. Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res Ther 2006;8(5):R153
   PubMed Web of Science ®Google Scholar
• Scott PA, Kingsley GH, Smith CM, et al. Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis 2007;66(10):1296-304
   PubMed Web of Science ®Google Scholar
• Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086
   PubMed Web of Science ®Google Scholar
• Salvo F, Fourrier-Reglat A, Bazin F, et al. Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther 2011;89(6):855-66
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296(13):1633-44
   PubMed Web of Science ®Google Scholar
• Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332(7553):1302-8
   PubMed Web of Science ®Google Scholar
• Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006;98(3):266-74
   PubMed Web of Science ®Google Scholar
• Hennekens CH, Borzak S. Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease. J Cardiovasc Pharmacol Ther 2008;13(1):41-50
   PubMed Web of Science ®Google Scholar
• Abraham NS, El-Serag HB, Hartman C, et al. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment Pharmacol Ther 2007;25(8):913-24
   PubMed Web of Science ®Google Scholar
• Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364(9450):2021-9
   PubMed Web of Science ®Google Scholar
• Varas-Lorenzo C, Riera-Guardia N, Calingaert B, et al. Myocardial infarction and use of individual Non-steroidal anti-inflamatory drugs: meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 2013; In press
   PubMedGoogle Scholar
• García Rodríguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008;52(20):1628-36
   PubMed Web of Science ®Google Scholar
• McGettigan P, Han P, Henry D. Cyclooxygenase-2 inhibitors and coronary occlusion–exploring dose-response relationships. Br J Clin Pharmacol 2006;62(3):358-65
   PubMed Web of Science ®Google Scholar
• Depont F, Fourrier A, Merliere Y, et al. The CADEUS study: methods and logistics. Pharmacoepidemiol Drug Saf 2007;16(5):571-80
   PubMed Web of Science ®Google Scholar
• Depont F, Fourrier A, Merliere Y, et al. Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study. Pharmacoepidemiol Drug Saf 2007;16(8):891-900
   PubMed Web of Science ®Google Scholar
• Moore N, Diris H, Martin K, et al. NSAID use profiles derived from reimbursement data in France. Therapie 2004;59(5):541-6
   PubMed Web of Science ®Google Scholar
• Moore N, Verschuren X, Montout C, et al. Excess costs related to non-steroidal anti-inflammatory drug utilization in general practice. Therapie 2000;55(1):133-6
   PubMed Web of Science ®Google Scholar
• Moore N. Place of OTC analgesics and NSAIDs in osteoarthritis. Inflammopharmacology 2003;11(4):355-62
   PubMedGoogle Scholar
• Fosbol EL, Gislason GH, Jacobsen S, et al. The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidemiol Drug Saf 2008;17(8):822-33
   PubMed Web of Science ®Google Scholar
• Duong M, Salvo F, Pariente A, et al. Usage patterns of "over the counter" versus prescription-strength non-steroidal anti-inflammatory drugs in France. Br J Clin Pharmacol 2013; In press
   Google Scholar
• Moore N, Charlesworth A, Van Ganse E, et al. Risk factors for adverse events in analgesic drug users: results from the PAIN study. Pharmacoepidemiol Drug Saf 2003;12(7):601-10
   PubMed Web of Science ®Google Scholar
• Moore N. Diclofenac potassium 12.5 mg tablets for mild to moderate pain and Fever : a review of its pharmacology, clinical efficacy and safety. Clin Drug Investig 2007;27(3):163-95
   PubMed Web of Science ®Google Scholar
• Moore N, Van Ganse E, Le Parc J, et al. The PAIN study: paracetamol, aspirin and ibuprofen new tolerability study. A large scale, randomized clinical trial comparing the tolerability of aspirin, ibuprofen and paracetamol for short-term analgesia. Clin Drug Investig 1999;18:89-98
   Web of Science ®Google Scholar
• Hasford J, Moore N, Hoye K. Safety and usage pattern of low-dose diclofenac when used as an over-the-counter medication: results of an observational cohort study in a community-based pharmacy setting. Int J Clin Pharmacol Ther 2004;42(8):415-22
   PubMed Web of Science ®Google Scholar
• FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345(6):433-42
   PubMed Web of Science ®Google Scholar
• Varas-Lorenzo C, Castellsague J, Stang MR, et al. The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada. Pharmacoepidemiol Drug Saf 2009;18(11):1016-25
   PubMed Web of Science ®Google Scholar
• Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006;113(16):1950-7
   PubMed Web of Science ®Google Scholar
• Fosbol EL, Folke F, Jacobsen S, et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 2010;3(4):395-405
   PubMed Web of Science ®Google Scholar
• van der Linden MW, van der Bij S, Welsing P, et al. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2009;68(5):668-73
   PubMed Web of Science ®Google Scholar
• Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes 2009;2(3):155-63
   PubMed Web of Science ®Google Scholar
• Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006;113(25):2906-13
   PubMed Web of Science ®Google Scholar
• Brophy JM, Levesque LE, Zhang B. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart 2007;93(2):189-94
   PubMed Web of Science ®Google Scholar
• Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005;142(7):481-9
   PubMed Web of Science ®Google Scholar
• Fosbol EL, Gislason GH, Jacobsen S, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009;85(2):190-7
   PubMed Web of Science ®Google Scholar
• Fosbol EL, Kober L, Torp-Pedersen C, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals. Expert Opin Drug Saf 2010;9(6):893-903
   PubMed Web of Science ®Google Scholar
• Moore N. No obvious extra cardiovascular risk associated with low-dose NSAIDs. Clin Pharmacol Ther 2009;86(6):600-1. author reply 2-4
   PubMed Web of Science ®Google Scholar
• de Forni M, Armand JP. Cardiotoxicity of chemotherapy. Curr Opin Oncol 1994;6(4):340-4
   PubMedGoogle Scholar
• Doroshow JH, Locker GY, Myers CE. Experimental animal models of adriamycin cardiotoxicity. Cancer Treat Rep 1979;63(5):855-60
   PubMedGoogle Scholar
• Ghalie RG, Edan G, Laurent M, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002;59(6):909-13
   PubMed Web of Science ®Google Scholar
• Kingwell E, Koch M, Leung B, et al. Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology 2010;74(22):1822-6
   PubMed Web of Science ®Google Scholar
• Koutinos G, Stathopoulos GP, Dontas I, et al. The effect of doxorubicin and its analogue mitoxantrone on cardiac muscle and on serum lipids: an experimental study. Anticancer Res 2002;22(2A):815-20
   PubMed Web of Science ®Google Scholar
• Blackshear JL, Davidman M, Stillman MT. Identification of risk for renal insufficiency from nonsteroidal anti-inflammatory drugs. Arch Intern Med 1983;143(6):1130-4
   PubMed Web of Science ®Google Scholar
• Whelton A. COX-2-specific inhibitors and the kidney: effect on hypertension and oedema. J Hypertens Suppl 2002;20(6):S31-5
   PubMedGoogle Scholar
• Ahmad SR, Kortepeter C, Brinker A, et al. Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf 2002;25(7):537-44
   PubMed Web of Science ®Google Scholar
• Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000;151(5):488-96
   PubMed Web of Science ®Google Scholar
• Brater DC. Resistance to loop diuretics. Why it happens and what to do about it. Drugs 1985;30(5):427-43
   PubMed Web of Science ®Google Scholar
• Laiwah AC, Mactier RA. Antagonistic effect of non-steroidal anti-inflammatory drugs on frusemide-induced diuresis in cardiac failure. Br Med J (Clin Res Ed) 1981;283(6293):714
   PubMed Web of Science ®Google Scholar
• Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000;160(6):777-84
   PubMed Web of Science ®Google Scholar
• Mangoni AA, Woodman RJ, Gaganis P, et al. Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community. Br J Clin Pharmacol 2010;69(6):689-700
   PubMed Web of Science ®Google Scholar
• Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009;169(2):141-9
   PubMed Web of Science ®Google Scholar
• Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004;363(9423):1751-6
   PubMed Web of Science ®Google Scholar
• Van den Ouweland FA, Gribnau FW, Meyboom RH. Congestive heart failure due to nonsteroidal anti-inflammatory drugs in the elderly. Age Ageing 1988;17(1):8-16
   PubMed Web of Science ®Google Scholar
• Koopmans PP, Thien T, Gribnau FW. The influence of ibuprofen, diclofenac and sulindac on the blood pressure lowering effect of hydrochlorothiazide. Eur J Clin Pharmacol 1987;31(5):553-7
   PubMed Web of Science ®Google Scholar
• Nishimura H, Kubo S, Ueyama M, et al. Effects of captopril on peripheral hemodynamics in severe congestive heart failure. Clin Exp Hypertens A 1987;9(2-3):587-91
   PubMed Web of Science ®Google Scholar
• Bhagat K. Effects of non-steroidal anti-inflammatory drugs on hypertension control using angiotensin converting enzyme inhibitors and thiazide diuretics. East Afr Med J 2001;78(10):507-9
   PubMedGoogle Scholar
• Palmer R, Weiss R, Zusman RM, et al. Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors. Am J Hypertens 2003;16(2):135-9
   PubMed Web of Science ®Google Scholar
• White WB. Defining the problem of treating the patient with hypertension and arthritis pain. Am J Med 2009;122(5 Suppl):S3-9
   PubMed Web of Science ®Google Scholar
• Webster J. Interactions of NSAIDs with diuretics and beta-blockers mechanisms and clinical implications. Drugs 1985;30(1):32-41
   PubMed Web of Science ®Google Scholar
• Krum H, Swergold G, Curtis SP, et al. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. J Hypertens 2009;27(4):886-93
   PubMed Web of Science ®Google Scholar
• Pavlicevic I, Kuzmanic M, Rumboldt M, et al. Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol 2008;15(3):e372-82
   PubMedGoogle Scholar
• Lee A, Cooper MG, Craig JC, et al. The effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on postoperative renal function: a meta-analysis. Anaesth Intensive Care 1999;27(6):574-80
   PubMed Web of Science ®Google Scholar
• Furey SA, Vargas R, McMahon FG. Renovascular effects of nonprescription ibuprofen in elderly hypertensive patients with mild renal impairment. Pharmacotherapy 1993;13(2):143-8
   PubMed Web of Science ®Google Scholar
• Murray MD, Black PK, Kuzmik DD, et al. Acute and chronic effects of nonsteroidal antiinflammatory drugs on glomerular filtration rate in elderly patients. Am J Med Sci 1995;310(5):188-97
   PubMed Web of Science ®Google Scholar
• Gurwitz JH, Everitt DE, Monane M, et al. The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons. J Gerontol A Biol Sci Med Sci 1996;51(2):M74-9
   PubMed Web of Science ®Google Scholar
• Thakur V, Cook ME, Wallin JD. Antihypertensive effect of the combination of fosinopril and HCTZ is resistant to interference by nonsteroidal antiinflammatory drugs. Am J Hypertens 1999;12(9 Pt 1):925-8
   PubMed Web of Science ®Google Scholar
• Minuz P, Lechi A, Arosio E, et al. Antihypertensive activity of enalapril. Effect of ibuprofen and different salt intakes. J Clin Hypertens 1987;3(4):645-53
   PubMed Web of Science ®Google Scholar
• Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153(4):477-84
   PubMedGoogle Scholar
• Aw TJ, Haas SJ, Liew D, et al. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005;165(5):490-6
   PubMed Web of Science ®Google Scholar
• Chan CC, Reid CM, Aw TJ, et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 2009;27(12):2332-41
   PubMed Web of Science ®Google Scholar
• Kawai S, Nishida S, Kato M, et al. Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur J Pharmacol 1998;347(1):87-94
   PubMed Web of Science ®Google Scholar
• Cronberg S, Wallmark E, Soderberg I. Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans. Scand J Haematol 1984;33(2):155-9
   PubMedGoogle Scholar
• Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004;109(12):1468-71
   PubMed Web of Science ®Google Scholar
• Tuleja E, Mejza F, Cmiel A, et al. Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men. Arterioscler Thromb Vasc Biol 2003;23(6):1111-15
   PubMed Web of Science ®Google Scholar
• Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345(25):1809-17
   PubMed Web of Science ®Google Scholar
• Waksman JC, Brody A, Phillips SD. Nonselective nonsteroidal antiinflammatory drugs and cardiovascular risk: are they safe? Ann Pharmacother 2007;41(7):1163-73
   PubMed Web of Science ®Google Scholar
• Watson DJ, Rhodes T, Cai B, et al. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002;162(10):1105-10
   PubMed Web of Science ®Google Scholar
• Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002;162(10):1111-15
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Gonzalez-Perez A. Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Med 2005;3:17
   PubMed Web of Science ®Google Scholar
• Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312(7046):1563-6
   PubMed Web of Science ®Google Scholar
• Houston MC, Weir M, Gray J, et al. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med 1995;155(10):1049-54
   PubMed Web of Science ®Google Scholar
• Combe B, Swergold G, McLay J, et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford) 2009;48(4):425-32
   PubMed Web of Science ®Google Scholar
• Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 2005;46(3):500-7
   PubMed Web of Science ®Google Scholar
• Varas-Lorenzo C, Riera-Guardia N, Calingaert B, et al. Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf 2011;20(12):1225-36
   PubMed Web of Science ®Google Scholar
• Solomon DH, Avorn J, Sturmer T, et al. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum 2006;54(5):1378-89
   PubMed Web of Science ®Google Scholar
• Roumie CL, Mitchel EF Jr, Kaltenbach L, et al. Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke. Stroke 2008;39(7):2037-45
   PubMed Web of Science ®Google Scholar
• Giuliano F, Warner TD. Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. Br J Pharmacol 1999;126(8):1824-30
   PubMed Web of Science ®Google Scholar
• Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998;104(5):413-21
   PubMed Web of Science ®Google Scholar
• Kato M, Nishida S, Kitasato H, et al. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol 2001;53(12):1679-85
   PubMed Web of Science ®Google Scholar
• Riendeau D, Percival MD, Brideau C, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001;296(2):558-66
   PubMed Web of Science ®Google Scholar
• Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999;96(13):7563-8
   PubMed Web of Science ®Google Scholar
• Morrison A, Ramey DR, van Adelsberg J, et al. Systematic review of trials of the effect of continued use of oral non-selective NSAIDs on blood pressure and hypertension. Curr Med Res Opin 2007;23(10):2395-404
   PubMed Web of Science ®Google Scholar
• Bavry AA, Khaliq A, Gong Y, et al. Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. Am J Med 2011;124(7):614-20
   PubMed Web of Science ®Google Scholar
• Schjerning Olsen AM, Fosbol EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 2011;123(20):2226-35
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284(10):1247-55
   PubMed Web of Science ®Google Scholar
• Lee KK, You JH, Ho JT, et al. Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease. Aliment Pharmacol Ther 2003;18(2):217-22
   PubMed Web of Science ®Google Scholar
• Rassen JA, Glynn RJ, Rothman KJ, et al. Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses. Pharmacoepidemiol Drug Saf. 2012;21:697-709
   PubMed Web of Science ®Google Scholar
• Rassen JA, Schneeweiss S. Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system. Pharmacoepidemiol Drug Saf 2012;21(Suppl 1):41-9
   PubMedGoogle Scholar
• Schneeweiss S, Rassen JA, Glynn RJ, et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009;20(4):512-22
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Solomon DH, Wang PS, et al. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. Arthritis Rheum 2006;54(11):3390-8
   PubMed Web of Science ®Google Scholar
• Rosenberg L, Rao RS, Palmer JR. A case-control study of acetaminophen use in relation to the risk of first myocardial infarction in men. Pharmacoepidemiol Drug Saf 2003;12(6):459-65
   PubMed Web of Science ®Google Scholar
• de Vries F, Setakis E, van Staa TP. Concomitant use of ibuprofen and paracetamol and the risk of major clinical safety outcomes. Br J Clin Pharmacol 2010;70(3):429-38
   PubMed Web of Science ®Google Scholar
• Rahme E, Nedjar H. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology (Oxford) 2007;46(3):435-8
   PubMed Web of Science ®Google Scholar
• Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006;113(12):1578-87
   PubMed Web of Science ®Google Scholar
• Sudano I, Flammer AJ, Periat D, et al. Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation 2010;122(18):1789-96
   PubMed Web of Science ®Google Scholar
• White WB, Campbell P. Blood pressure destabilization on nonsteroidal antiinflammatory agents: acetaminophen exposed? Circulation 2010;122(18):1779-81
   PubMed Web of Science ®Google Scholar